List of Tables
Table 1. Neuromyelitis Optica Drug Market Trends
Table 2. Neuromyelitis Optica Drug Market Drivers & Opportunity
Table 3. Neuromyelitis Optica Drug Market Challenges
Table 4. Neuromyelitis Optica Drug Market Restraints
Table 5. Global Neuromyelitis Optica Drug Revenue by Company (2020-2025) & (US$ Million)
Table 6. Global Neuromyelitis Optica Drug Revenue Market Share by Company (2020-2025)
Table 7. Key Companies Neuromyelitis Optica Drug Manufacturing Base Distribution and Headquarters
Table 8. Key Companies Neuromyelitis Optica Drug Product Type
Table 9. Key Companies Time to Begin Mass Production of Neuromyelitis Optica Drug
Table 10. Global Neuromyelitis Optica Drug Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuromyelitis Optica Drug as of 2024)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global Neuromyelitis Optica Drug Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
Table 14. Global Neuromyelitis Optica Drug Sales Value by Type (2020-2025) & (US$ Million)
Table 15. Global Neuromyelitis Optica Drug Sales Value by Type (2026-2031) & (US$ Million)
Table 16. Global Neuromyelitis Optica Drug Sales Market Share in Value by Type (2020-2025)
Table 17. Global Neuromyelitis Optica Drug Sales Market Share in Value by Type (2026-2031)
Table 18. Global Neuromyelitis Optica Drug Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
Table 19. Global Neuromyelitis Optica Drug Sales Value by Application (2020-2025) & (US$ Million)
Table 20. Global Neuromyelitis Optica Drug Sales Value by Application (2026-2031) & (US$ Million)
Table 21. Global Neuromyelitis Optica Drug Sales Market Share in Value by Application (2020-2025)
Table 22. Global Neuromyelitis Optica Drug Sales Market Share in Value by Application (2026-2031)
Table 23. Global Neuromyelitis Optica Drug Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
Table 24. Global Neuromyelitis Optica Drug Sales Value by Region (2020-2025) & (US$ Million)
Table 25. Global Neuromyelitis Optica Drug Sales Value by Region (2026-2031) & (US$ Million)
Table 26. Global Neuromyelitis Optica Drug Sales Value by Region (2020-2025) & (%)
Table 27. Global Neuromyelitis Optica Drug Sales Value by Region (2026-2031) & (%)
Table 28. Key Countries/Regions Neuromyelitis Optica Drug Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
Table 29. Key Countries/Regions Neuromyelitis Optica Drug Sales Value, (2020-2025) & (US$ Million)
Table 30. Key Countries/Regions Neuromyelitis Optica Drug Sales Value, (2026-2031) & (US$ Million)
Table 31. Pfizer Basic Information List
Table 32. Pfizer Description and Business Overview
Table 33. Pfizer Neuromyelitis Optica Drug Products, Services and Solutions
Table 34. Revenue (US$ Million) in Neuromyelitis Optica Drug Business of Pfizer (2020-2025)
Table 35. Pfizer Recent Developments
Table 36. Fresenius Basic Information List
Table 37. Fresenius Description and Business Overview
Table 38. Fresenius Neuromyelitis Optica Drug Products, Services and Solutions
Table 39. Revenue (US$ Million) in Neuromyelitis Optica Drug Business of Fresenius (2020-2025)
Table 40. Fresenius Recent Developments
Table 41. Teva Basic Information List
Table 42. Teva Description and Business Overview
Table 43. Teva Neuromyelitis Optica Drug Products, Services and Solutions
Table 44. Revenue (US$ Million) in Neuromyelitis Optica Drug Business of Teva (2020-2025)
Table 45. Teva Recent Developments
Table 46. Sandoz Basic Information List
Table 47. Sandoz Description and Business Overview
Table 48. Sandoz Neuromyelitis Optica Drug Products, Services and Solutions
Table 49. Revenue (US$ Million) in Neuromyelitis Optica Drug Business of Sandoz (2020-2025)
Table 50. Sandoz Recent Developments
Table 51. Intas Basic Information List
Table 52. Intas Description and Business Overview
Table 53. Intas Neuromyelitis Optica Drug Products, Services and Solutions
Table 54. Revenue (US$ Million) in Neuromyelitis Optica Drug Business of Intas (2020-2025)
Table 55. Intas Recent Developments
Table 56. Gyjtrs Basic Information List
Table 57. Gyjtrs Description and Business Overview
Table 58. Gyjtrs Neuromyelitis Optica Drug Products, Services and Solutions
Table 59. Revenue (US$ Million) in Neuromyelitis Optica Drug Business of Gyjtrs (2020-2025)
Table 60. Gyjtrs Recent Developments
Table 61. NANG KUANG Basic Information List
Table 62. NANG KUANG Description and Business Overview
Table 63. NANG KUANG Neuromyelitis Optica Drug Products, Services and Solutions
Table 64. Revenue (US$ Million) in Neuromyelitis Optica Drug Business of NANG KUANG (2020-2025)
Table 65. NANG KUANG Recent Developments
Table 66. Tianjin Kingyork Basic Information List
Table 67. Tianjin Kingyork Description and Business Overview
Table 68. Tianjin Kingyork Neuromyelitis Optica Drug Products, Services and Solutions
Table 69. Revenue (US$ Million) in Neuromyelitis Optica Drug Business of Tianjin Kingyork (2020-2025)
Table 70. Tianjin Kingyork Recent Developments
Table 71. Baxter Basic Information List
Table 72. Baxter Description and Business Overview
Table 73. Baxter Neuromyelitis Optica Drug Products, Services and Solutions
Table 74. Revenue (US$ Million) in Neuromyelitis Optica Drug Business of Baxter (2020-2025)
Table 75. Baxter Recent Developments
Table 76. CSL Basic Information List
Table 77. CSL Description and Business Overview
Table 78. CSL Neuromyelitis Optica Drug Products, Services and Solutions
Table 79. Revenue (US$ Million) in Neuromyelitis Optica Drug Business of CSL (2020-2025)
Table 80. CSL Recent Developments
Table 81. Grifols Basic Information List
Table 82. Grifols Description and Business Overview
Table 83. Grifols Neuromyelitis Optica Drug Products, Services and Solutions
Table 84. Revenue (US$ Million) in Neuromyelitis Optica Drug Business of Grifols (2020-2025)
Table 85. Grifols Recent Developments
Table 86. Octapharma Basic Information List
Table 87. Octapharma Description and Business Overview
Table 88. Octapharma Neuromyelitis Optica Drug Products, Services and Solutions
Table 89. Revenue (US$ Million) in Neuromyelitis Optica Drug Business of Octapharma (2020-2025)
Table 90. Octapharma Recent Developments
Table 91. CBOP Basic Information List
Table 92. CBOP Description and Business Overview
Table 93. CBOP Neuromyelitis Optica Drug Products, Services and Solutions
Table 94. Revenue (US$ Million) in Neuromyelitis Optica Drug Business of CBOP (2020-2025)
Table 95. CBOP Recent Developments
Table 96. Key Raw Materials Lists
Table 97. Raw Materials Key Suppliers Lists
Table 98. Neuromyelitis Optica Drug Downstream Customers
Table 99. Neuromyelitis Optica Drug Distributors List
Table 100. Research Programs/Design for This Report
Table 101. Key Data Information from Secondary Sources
Table 102. Key Data Information from Primary Sources
Table 103. Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Neuromyelitis Optica Drug Product Picture
Figure 2. Global Neuromyelitis Optica Drug Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Global Neuromyelitis Optica Drug Sales Value (2020-2031) & (US$ Million)
Figure 4. Neuromyelitis Optica Drug Report Years Considered
Figure 5. Global Neuromyelitis Optica Drug Players Revenue Ranking (2024) & (US$ Million)
Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Neuromyelitis Optica Drug Revenue in 2024
Figure 7. Neuromyelitis Optica Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 8. Glucocorticoids Picture
Figure 9. Immunotherapies Picture
Figure 10. Others Picture
Figure 11. Global Neuromyelitis Optica Drug Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
Figure 12. Global Neuromyelitis Optica Drug Sales Value Market Share by Type, 2024 & 2031
Figure 13. Product Picture of Acute Attack
Figure 14. Product Picture of Remission Prophylactic Treatment
Figure 15. Global Neuromyelitis Optica Drug Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
Figure 16. Global Neuromyelitis Optica Drug Sales Value Market Share by Application, 2024 & 2031
Figure 17. North America Neuromyelitis Optica Drug Sales Value (2020-2031) & (US$ Million)
Figure 18. North America Neuromyelitis Optica Drug Sales Value by Country (%), 2024 VS 2031
Figure 19. Europe Neuromyelitis Optica Drug Sales Value, (2020-2031) & (US$ Million)
Figure 20. Europe Neuromyelitis Optica Drug Sales Value by Country (%), 2024 VS 2031
Figure 21. Asia Pacific Neuromyelitis Optica Drug Sales Value, (2020-2031) & (US$ Million)
Figure 22. Asia Pacific Neuromyelitis Optica Drug Sales Value by Region (%), 2024 VS 2031
Figure 23. South America Neuromyelitis Optica Drug Sales Value, (2020-2031) & (US$ Million)
Figure 24. South America Neuromyelitis Optica Drug Sales Value by Country (%), 2024 VS 2031
Figure 25. Middle East & Africa Neuromyelitis Optica Drug Sales Value, (2020-2031) & (US$ Million)
Figure 26. Middle East & Africa Neuromyelitis Optica Drug Sales Value by Country (%), 2024 VS 2031
Figure 27. Key Countries/Regions Neuromyelitis Optica Drug Sales Value (%), (2020-2031)
Figure 28. United States Neuromyelitis Optica Drug Sales Value, (2020-2031) & (US$ Million)
Figure 29. United States Neuromyelitis Optica Drug Sales Value by Type (%), 2024 VS 2031
Figure 30. United States Neuromyelitis Optica Drug Sales Value by Application (%), 2024 VS 2031
Figure 31. Europe Neuromyelitis Optica Drug Sales Value, (2020-2031) & (US$ Million)
Figure 32. Europe Neuromyelitis Optica Drug Sales Value by Type (%), 2024 VS 2031
Figure 33. Europe Neuromyelitis Optica Drug Sales Value by Application (%), 2024 VS 2031
Figure 34. China Neuromyelitis Optica Drug Sales Value, (2020-2031) & (US$ Million)
Figure 35. China Neuromyelitis Optica Drug Sales Value by Type (%), 2024 VS 2031
Figure 36. China Neuromyelitis Optica Drug Sales Value by Application (%), 2024 VS 2031
Figure 37. Japan Neuromyelitis Optica Drug Sales Value, (2020-2031) & (US$ Million)
Figure 38. Japan Neuromyelitis Optica Drug Sales Value by Type (%), 2024 VS 2031
Figure 39. Japan Neuromyelitis Optica Drug Sales Value by Application (%), 2024 VS 2031
Figure 40. South Korea Neuromyelitis Optica Drug Sales Value, (2020-2031) & (US$ Million)
Figure 41. South Korea Neuromyelitis Optica Drug Sales Value by Type (%), 2024 VS 2031
Figure 42. South Korea Neuromyelitis Optica Drug Sales Value by Application (%), 2024 VS 2031
Figure 43. Southeast Asia Neuromyelitis Optica Drug Sales Value, (2020-2031) & (US$ Million)
Figure 44. Southeast Asia Neuromyelitis Optica Drug Sales Value by Type (%), 2024 VS 2031
Figure 45. Southeast Asia Neuromyelitis Optica Drug Sales Value by Application (%), 2024 VS 2031
Figure 46. India Neuromyelitis Optica Drug Sales Value, (2020-2031) & (US$ Million)
Figure 47. India Neuromyelitis Optica Drug Sales Value by Type (%), 2024 VS 2031
Figure 48. India Neuromyelitis Optica Drug Sales Value by Application (%), 2024 VS 2031
Figure 49. Neuromyelitis Optica Drug Industrial Chain
Figure 50. Neuromyelitis Optica Drug Manufacturing Cost Structure
Figure 51. Channels of Distribution (Direct Sales, and Distribution)
Figure 52. Bottom-up and Top-down Approaches for This Report
Figure 53. Data Triangulation
Figure 54. Key Executives Interviewed
